CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 174 enrolled
Drug / intervention
Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03689920
NCT03689920N/ACompleted
CompareCT.gov

Study to Demonstrate the Value of Multiple Modalities and Combining Mechanisms Using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

Boston Scientific Corporation·interventional·Posted Oct 1, 2018·Updated Jan 11, 2022

In Brief

A clinical study evaluating Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System for Chronic Pain and Back Pain. Completed, enrolled 174 participants across 15 sites.

Detailed Summary

To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain, Back Pain
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 1, 2018
Enrollment StartOct 3, 2018
Primary CompletionNov 5, 2019
Study CompletionDec 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago

Interventions

Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) Systemdevice

The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.